After critics lambasted Gilead for grabbing the FDA's special rare drug status on remdesivir, they're giving it back
Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.
The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.